Our scRNA-seq profiling of control or erdafitinib-treated UPFL tumors demonstrates that oncogenic FGFR3 alterations drive a luminal phenotype in all urothelial tumor cell types, suggesting that FGFR inhibition may impact a broad range of tumor cell types. Here, FGFR3 is linked to neoplasm.